摘要
目的探讨耐药基因产物P-糖蛋白(P-gp)与新辅助化疗治疗子宫内膜癌疗效的相关性。方法选择接受新辅助化疗的子宫内膜癌患者67例作为观察组,同期体检的68名健康妇女作为对照组。比较两组患者的P-gp表达情况。结果观察组P-gp阳性率为64.2%,对照组P-gp阳性率为1.5%;观察组P-gp表达阴性患者化疗后完全缓解(CR)11人,部分缓解(PR)11人,稳定(SD)1人,进展(PD)1人;P-gp表达阳性患者化疗后CR 13人,PR 8人,SD 19人,PD 3人。P-gp表达阴性患者的疗效显著高于P-gp表达阳性患者(z=2.550,P=0.011);P-gp表达阳性患者与P-gp表达阴性患者的临床病理因素比较,差异无统计学意义(P>0.05)。结论 P-糖蛋白与子宫内膜癌患者新辅助化疗的疗效密切相关。
Objective To analysis the relevance between resistance gene product P- glycoprotein （P-gp） and curative effects for neoadjuvant chemotherapy in the treatment of endometrial carcinoma patients. Methods 67 cases of endometrial cancer patients who undergo neoadjuvant chemotherapy in our hospital were selected as the observation group, 68 healthy women who physical examinationed in our hospital at the same time as control group. The P-gp expression of two group patients were compared. Results The posi- tive rate of P-gp in the observation group was 64. 2%, the positive rate of P-gp in the control group was 1.5% ; The patients of P-gp negative in observation group after chemotherapy ,CR 11, PR 11, SD 1, PD 1. The patients in positive expression of P-gp in observation group after chemotherapy, CR 13, PR 8, SD 19, PD 3. P-gp positive patients was significantly higher than that in P-gp positive expression patients （z = 2. 550, P = 0. 011 ） ; The clinical pathological factors of P-gp positive patients and P-gp negative patients were compared, the difference was not statistically significant （ P 〉 0. 05 ）. Conclusions The P-glycopro- tein closely related to curative effect for neoadjuvant chemotherapy in endomctrial cancer patients.
出处
《中国肿瘤临床与康复》
2013年第2期116-118,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
子宫内膜癌
药物疗法
疗效
Endometrial cancer
Drug therapy
Curative effect
